摘要
目的:评价还原型谷胱甘肽治疗酒精性肝病的有效性和安全性。方法:计算机检索相关数据库以及手工检索10种肝病杂志和有关学术会议论文汇编。纳入还原型谷胱甘肽治疗酒精性肝病的随机对照试验,并对纳入研究方法学质量进行评价,同时采用RevMan4.2.8软件对相关数据进行Meta分析。结果:纳入随机对照试验11篇。国产还原型谷胱甘肽与进口还原型谷胱甘肽相比,临床疗效及不良反应差异无显著性,总有效率(RR0.97,95%CI0.90,1.05);还原型谷胱甘肽与空白、门冬氨酸钾镁、甘草酸二铵相比,临床疗效明显优于对照组,总有效率分别为(RR1.43,95%CI1.13,1.81)、(RR1.54,95%CI1.25,1.89)、(RR1.35,95%CI1.04,1.74),不良反应方面差异无统计学意义。结论:国产还原型谷胱甘肽在治疗酒精性肝病疗效和安全性上与进口还原型谷胱甘肽相似;与对照组相比,还原型谷胱甘肽可明显提高治疗疗效,同时无相关不良反应出现。
OBJECTIVE To evaluate the curative effect and safety of reduced glutathione for alcoholic liver disease. METH- -ODS We searched relevant data bases, meanwhile ten Chinese medical journals and interrelated academic conference proceed ings were searched by manual method. The quality evaluation of studies and the data analysis followed the methods of the Coehrane Collaboration. Meta - analysis was performed by RevMan 4. 2.8 software. RESULTS Eleven studies were included. The recta-analysis showed that.. （1） Domestic glutathione was not significantly different from imported glutathione in clinical efficacy and adverse effects, total effective rate （RR 0. 97, 95% CI 0. 90 to 1.05）. （2） compared with placebo, potassium magnessium aspartate and diarnmonium glycyrrhizinate group, the clinical efficacy was significantly higher for reduced glutathione group, total effective rate （RR 1.43, 95% CI 1.13 to 1.81）, （RR 1.54, 95% CI 1.25 to 1.89） and （RR 1.35, 95% CI 1.04 to 1.74） respectively, but there were no significant differences in adverse effects. CONCLUSION Domestic glutathione was similar to imported glutathione in clinical efficacy and safety; compared with placebo, potassium magnessium aspartate and diammonium glycyrrhizinate, glutathione can significantly improve clinical efficacy, and no relevant adverse effects emerged.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2008年第11期912-916,共5页
Chinese Journal of Hospital Pharmacy
关键词
酒精性肝病
还原型谷胱甘肽
谷胱甘肽
系统评价
alcoholic liver disease
reduced glutathione
glutathione
systematic evaluation
